6864.TWO Anti-Microbial Savior BioteQ Co., Ltd.

Healthcare Biotechnology Taiwan OTC Exchange
33.95 TWD
Close of Nov 6, 2026
32.95 87.00
Market cap
TWD 1.29B
P/E
-
P/B
2.98x
ROE
-18.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6864.TWO undervalued?

Graham number

The Graham number of Anti-Microbial Savior BioteQ Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Anti-Microbial Savior BioteQ Co., Ltd. fundamental analysis

No fundamental analysis for Anti-Microbial Savior BioteQ Co., Ltd. yet.

Anti-Microbial Savior BioteQ Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Anti-Microbial Savior BioteQ Co., Ltd.

Anti-Microbial Savior BioteQ Co., Ltd. focuses on the research and development of pharmaceutical drug products in Taiwan. The company offers PoroVance precision pore engineering and small-molecule drug discovery. Its pipeline products include FORMOSA-1117, antibacterial drug candidate; YUAN-03, antiviral drug candidate; AMS-2140, broad-spectrum antiviral drug candidate; TenTacle, ADC linker-conjugate compound. Anti-Microbial Savior BioteQ Co., Ltd. was founded in 2018 and is…

Full company profile